eViralHepatitis Review
HOME        CME INFORMATION        PROGRAM DIRECTORS        NEWSLETTER ARCHIVE        EDIT PROFILE        RECOMMEND TO A COLLEAGUE
  VOLUME 2 – ISSUE 8
Human Immunodeficiency Virus and Hepatitis C Virus Coinfection
Our guest author is Mark Sulkowski, MD, Professor of Medicine, Medical Director of the Viral Hepatitis Center, Division of Infectious Diseases and Gastroenterology/Hepatology at the Johns Hopkins University School of Medicine in Baltimore, Maryland.

After completing this activity, the participant will demonstrate the ability to:

Describe the epidemiology of HCV infection in HIV-infected persons including the role of sexual transmission of HCV
Discuss the use of HCV NS3/4A protease inhibitors for the treatment of chronic HCV infection in HIV-infected persons
Explain the rationale for staging and methodologies used to stage, HCV-related liver disease.

This discussion, offered as a downloadable audio file and companion transcript, covers the important issues related to Human Immunodeficiency Virus and hepatitis C virus coinfection in the format of case-study scenarios for the clinical practice. This program is a follow up to the Volume 2, Issue 7 eViralHepatitis Review newsletter —Human Immunodeficiency Virus and Hepatitis C Virus Coinfection.


Unlabeled/Unapproved Uses
Dr. Sulkowski also notes that his presentation today will include a discussion of the off-label or unapproved uses of telaprevir and boceprevir.
Kenneth E. Sherman, MD, PhD

Mark S. Sulkowski, MD
Professor of Medicine
Medical Director of the
Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology/Hepatology
The Johns Hopkins University
School of Medicine
Baltimore, Maryland


Faculty Disclosure
Dr. Sulkowski has disclosed that he has served as a consultant for Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., BMS, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, and Vertex Pharmaceuticals. He has also received grants and/or research support from Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., BMS, Gilead, Janssen, Merck, Roche and Vertex Pharmaceuticals.

Release Date
July 31, 2012
Expiration Date
July 30, 2013
 
Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Divisions of Infectious Disease and Gastroenterology/Hepatology
The Johns Hopkins University School
of Medicine
Baltimore, Maryland
Raymond T. Chung, MD
Associate Professor of Medicine
Director of Hepatology, Medicine Services
Harvard Medical School
Vice Chief of Gastroenterology
Massachusetts General Hospital
Boston, Massachusetts
Julie McArthur, MS, CRNP
Adult Nurse Practitioner
Division of Infectious Disease
The Johns Hopkins University School
of Medicine
Baltimore, Maryland
 Accreditation Statements
Physicians
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Nurses
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.


credit designations
Physicians
eNewsletter: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category1 Credit(s)�. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Podcast:
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)�. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Newsletter: This 1 contact hour Educational Activity is provided by The Institute for Johns Hopkins Nursing. Each newsletter carries a maximum of 1 contact hour or a total of 7 contact hours for the 7 newsletters in this program.

Podcast: This 0.5 contact hour Educational Activity is provided by the Institute for Johns Hopkins Nursing. Each podcast carries a maximum of 0.5 contact hour or a total of 2.5 contact hours for the 5 podcasts in this program.


Successful Completion
To successfully complete this activity, participants must read the content, and then link to the Johns Hopkins University School of Medicine's website or the Institute for Johns Hopkins Nursing’s website to complete the post-test and evaluation. Once you receive a passing grade, you can access and print your certificate of credit.

NOTE: If you have already registered for other Hopkins CME programs on their prospective websites simply enter the requested information when prompted.

There are no fees or prerequisites for this activity.

This activity is supported by an educational grant from Gilead Sciences, Inc. and Vertex Pharmaceuticals.


Launch Date
December 15, 2011; activities expire 2 years from the date of publication.

Length of Activity: 30 minutes


Internet CME Policy
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. The Johns Hopkins University SOM maintains its Internet site as an information resource and service for physicians, other health professionals, and the public.

Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in an Internet-based CME program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine program. CME collects only the information necessary to provide you with the services that you request.


Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information for specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.


Statement of Responsibility
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

Intended Audience
This activity has been developed for hepatologists, primary care physicians, infectious disease specialists, nurses, nurse practitioners, and others involved in the care of patients with viral hepatitis.

Planner disclosures
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships, regardless of their relevance to the activity content. Faculty are required to disclose only those relationships that are relevant to their specific presentations. The following relationships have been reported for this activity:
Mark S. Sulkowski, MD, has disclosed that he has served as a consultant for Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers-Squibb, Janssen, Merck, Novartis, Pfizer, Roche, and Vertex Pharmaceuticals. He has also received grants and research support from Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers-Squibb, Gilead, Janssen, Merck, Roche, and Vertex Pharmaceuticals.
Raymond T. Chung, MD, has disclosed that he has received grants/research support from Gilead, Pfizer, Roche/Genentech, Merck, and Romark.
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Guest Author Disclosures

Confidentiality Disclaimer for CME Conference Attendees
I certify that I am attending a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to “protected health information,” as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person�s health or treatment that identifies the person.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”

For CME Questions, please contact the CME Office at (410) 955-2959 or e-mail cmenet@jhmi.edu.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195

Reviewed & Approved by:
General Counsel, Johns Hopkins Medicine (4/1/03)

Updated 4/09


hardware & software requirements
Pentium 800 processor or greater, Windows 98/NT/2000/XP/7 or Mac OS 9/X, Microsoft Internet Explorer 5.5 or later, 56K or better modem, Windows Media Player 9.0 or later, 128 MB of RAM, sound card and speakers, Adobe Acrobat Reader, storage, Internet connectivity, and minimum connection speed. Monitor settings: High color at 800 x 600 pixels.
Listen
If you want to now listen to the eViralHepatitis Review podcast, just click on the button above. This will open your Internet browser to play the podcast by streaming the media via the web.

Please note: This podcast file is large so please be patient while the content downloads.
Download
Save the podcast to your computer. Once saved you can manage and play the file like any song or music using your music software (iTunes, Windows Media, Real Player, etc.). You can also transfer the podcast file to your iPod, MP3 player and listen while on-the-go.
Subscribe
Like any RSS subscription,
when you subscribe to
this Review you will automatically receive each new edition, downloaded to your hard drive as soon as it becomes available. You may manage and play the downloaded podcast file like any song or audio file by using your music software (iTunes, Windows Media, Real Player, etc.). You can also transfer the podcast file to your iPod, MP3 player to listen while on-the-go.
Subscribe to eViralHepatitis Review
COMPLETE THE
POST-TEST


Step 1. Click on the appropriate link below. This will take you to the post-test.

Step 2. If you have participated in a Johns Hopkins on-line course, login. Otherwise, please register.

Step 3. Complete the post-test and course evaluation.

Step 4. Print out your certificate.
Physicians Post-test
Nurse Post-test
eViralHepatitis Review Newsletter Archive
»Download the podcast transcript
»Go to the companion newsletter
»Learn more about podcasting
 
Help other ID specialists and primary care clinicians find solutions to the diagnosis and treatment of viral hepatitis. Forward a link to the eViralHepatitis Review website to a colleague.
Share with a colleague
  Next Issue: Reactivation of Hepatitis B
 
© 2012 JHUSOM, IJHN and eViralHepatitis Review

Presented by JHUSOM and IJHN in collaboration with DKBmed.